BACE1 and early-onset autosomal dominant Alzheimer disease: Therefore, as it catalyzes the initial site-specific hydrolysis step of Aβ production, BACE-1 is an attractive therapeutic target for the treatment of Alzheimer’s disease [1–3,16,17].